Background: To evaluate the long-term efficacy and toxicity of radiation therapy in patients with Stage IE primary ocular adnexal mucosa-associated lymphoid tissue lymphoma.
Methods: We designed a retrospective analysis to evaluate 81 patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy between 2006 and 2016. The median radiation dose was 30 Gy (range, 30-36 Gy in 15-18 fractions). Local control, progression-free survival, overall survival, and cumulative incidence of Grade 3 cataract were calculated by using the Kaplan-Meier method.
Result: The median follow-up time was 74 months (range, 4-157 months). The 5-year local control was 100%. Although local relapse was suspected in 3 patients after radiation therapy, 2 patients were pathologically diagnosed as IgG4-related inflammation and in 1 patient as intense inflammatory cell infiltration. The 5-year progression-free survival was 94.4%. Five patients had relapse at distant sites. The 5-year overall survival was 98.8%. Twenty patients had Grade 3 cataract. The 5-year cumulative incidences of Grade ≥ 3 and Grade ≥ 2 cataract for 58 patients treated without a lens shield were 38 and 40%, respectively. The incidence of Grade ≥ 3 cataract was 42% for 50 patients treated with 6-MV X-rays (estimated lens dose: 29 Gy) and 17% for 8 patients treated with 9-MeV electrons (estimated lens dose: 24 Gy).
Conclusions: Radiation therapy alone yielded excellent local control and long-term survival in Stage IE ocular adnexal mucosa-associated lymphoid tissue lymphoma. Long-term observation with careful attention to relapse at distant sites is necessary. In the case of suspected local relapse, IgG4-related disease should be carefully ruled out.
Keywords: Cataract; MALT lymphoma; Ocular adnexal; Radiation therapy.
Conflict of interest statement
The authors declare that they have no competing interests.
Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes.Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1382-91. doi: 10.1016/s0360-3016(03)00767-3. Int J Radiat Oncol Biol Phys. 2003. PMID: 14630277
Outcomes of primary lymphoma of the ocular adnexa (orbital lymphoma) treated with radiotherapy.Clin Oncol (R Coll Radiol). 2015 Mar;27(3):153-9. doi: 10.1016/j.clon.2014.10.002. Epub 2014 Oct 29. Clin Oncol (R Coll Radiol). 2015. PMID: 25455843
Long-term outcome and patterns of failure in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy.Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1509-14. doi: 10.1016/j.ijrobp.2011.04.052. Epub 2011 Jun 12. Int J Radiat Oncol Biol Phys. 2012. PMID: 21664061
Curative radiotherapy for primary orbital lymphoma.Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):818-23. doi: 10.1016/s0360-3016(02)02966-8. Int J Radiat Oncol Biol Phys. 2002. PMID: 12377334 Review.
Treatments for Ocular Adnexal Lymphoma: A Report by the American Academy of Ophthalmology.Ophthalmology. 2018 Jan;125(1):127-136. doi: 10.1016/j.ophtha.2017.05.037. Epub 2017 Jul 14. Ophthalmology. 2018. PMID: 28712656 Review.